Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE Interestingly, cells carrying the BRAF(V600E) mutation were not only found among cells surrounding the primary tumor but were also present in the stroma of melanoma metastases as well as in a histologically tumor-free re-excision sample from a patient who subsequently developed a local recurrence. 27338362

2016

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE In summary, this study provides a mechanistic basis for targeting Mek and not B-Raf in the mutant (V600E)B-Raf signaling cascade to inhibit melanoma metastases. 16912199

2006

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE BRAF(V600E) significantly correlated with absence of node metastasis. 16452550

2006

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE However, there was no significant association between BRAF(V600E) mutation and factors including age > 45 (OR = 0.98; 95%CI = 0.89-1.07), tumor size (OR = 0.84; 95%CI = 0.64-1.09) and distant metastasis (OR = 1.23; 95%CI = 0.67-2.27). 26871894

2016

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE The prevalence of BRAF(V600E) mutation of PTMCs with high aggressiveness (advanced disease stages, extrathyroidal extension, and nodal metastasis) was significantly higher (p < 0.05) than that of PTMCs without aggressive behavior. 19034577

2009

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE We describe 3 patients with BRAF V600E mutation metastatic melanoma in whom treatment with vemurafenib resulted in prompt extracranial disease response but progression of metastatic disease in the brain. 23036672

2012

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE Detection of B-raf exon 15 mutations or prediction of the activating mutation V599E were not statistically associated with the risk for subsequent metastasis in the follow-up of patients. 15331929

2004

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE There were significant differences in clinicopathological parameters, such as extrathyroidal extension (P=0.031), nodal metastasis (P=0.021) and BRAF(V600E) mutation (P=0.039), between NF-κB-positive and negative PTCs. 23528368

2013

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE Our results provide support for the role of BRAF(V600E) in metastasis and suggest that inhibiting invasion is a potential therapeutic strategy against melanoma. 27210749

2016

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE The TERT promoter mutation is an independent predictor for distant metastasis of WDTC, but ALK testing is not useful for clinical decision-making in Korean patients with a high prevalence of the BRAF V600E mutation. 26857243

2016

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE None of the 30 metastases and 10 primary uveal melanomas tested expressed the V599E mutation. 14522889

2003

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE BRAF V600E gene mutation was documented in this lesion, and the patient received vemurafenib, with dramatic improvement noted on positron emission tomography scan after 2 months of treatment, soon followed by development of extensive metastases, including to brain. 23715079

2013

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE Here, we show intralesional molecular heterogeneity in a progressing V600E BRAF-mutant melanoma metastasis from a patient treated for 7 months with the BRAF inhibitor vemurafenib. 22962325

2012

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE In patients with conventional papillary thyroid cancer, BRAF V600E mutation was associated with older age (P = 0.0381), lymph node metastasis (P = 0.0323), distant metastasis (P = 0.045), higher TNM stage (I and II vs. III and IV, P = 0.0389), and recurrent and persistent disease (P = 0.009) with a median follow-up time of 6.0 years. 17717450

2007

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE The combinatorial treatment of PLX4032 and PHA665752, a c-Met inhibitor reversed EMT.Similar results were confirmed in vivo. c-Met-mediated reactivation of the PI3K/AKT pathway contributes to the drug resistance to PLX4032 in BRAF (V600E) mutant anaplastic thyroid cancer cells and further promotes tumor cell migration and invasion by upregulated EMT mechanism. 27880942

2017

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE In this study, the occurrence and percentage of the BRAF V600E mutated allele was not preferentially associated with the development of metastases and the average mutated allele percentage decreased as the tumor progresses from the primary site to the lymph node metastatic sites. 23533235

2013

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE Unexpectedly, V599 and V599E mutations were absent in cutaneous/subcutaneous metastases derived from acrolentiginous melanomas as preceding primary tumours. 15935100

2005

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE Overall median survival time (MST), stratified for variables, including BRAF V600E mutation and eligibility for treatments with new immunotherapy drugs, was retrospectively assessed in 41 patients with pelvic melanoma loco regional metastases. 29120401

2017

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE We also studied the role of BRAF V600E mutation in a set of melanoma patients who had been investigated for sentinel node metastasis. 25442222

2015

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE BRAF(V600E) mutation is predictive for distant metastasis in papillary thyroid carcinoma but not positively. 23981603

2013

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE BRAF V600E mutation was identified in 1% of patients only. p53 protein was lowly expressed in TGCT metastases compared to the matched primary tumors. 27085458

2016

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE The BRAF (V600E) mutation was associated with aggressive clinical behaviors including extrathyroid invasion, lymph nodal metastasis and tumor multifocality. 23179992

2013

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE In this study we compared drug responses to RAF and MEK inhibitors on tumor cell migration in 2D and 3D culture of BRAF(V600E) mutant cell lines derived from human papillary (BCPAP) and anaplastic (SW1736) thyroid carcinomas. 26384551

2015

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE Concordance in BRAF V600E status over time in malignant melanoma and corresponding metastases. 29119584

2018

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE In conclusion, B-Raf(V600E) plays an important role in PTC progression through genes (i.e., TSP-1) important in tumor invasion and metastasis. 20498063

2010